-$1.18 Earnings Per Share Expected for Theravance Biopharma Inc (TBPH) This Quarter

Share on StockTwits

Wall Street brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to announce earnings per share (EPS) of ($1.18) for the current quarter, Zacks reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.25) and the highest estimate coming in at ($1.06). Theravance Biopharma posted earnings of ($1.22) per share during the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is expected to announce its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Theravance Biopharma will report full year earnings of ($4.66) per share for the current financial year, with EPS estimates ranging from ($5.20) to ($3.47). For the next year, analysts forecast that the company will post earnings of ($4.63) per share, with EPS estimates ranging from ($6.10) to ($3.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Theravance Biopharma.

A number of research analysts have commented on TBPH shares. ValuEngine cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 22nd. BidaskClub raised shares of Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Cantor Fitzgerald started coverage on shares of Theravance Biopharma in a research report on Monday, January 28th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Zacks Investment Research cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $43.40.

In other news, SVP Sharathchandra S. Hegde sold 9,033 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total transaction of $223,205.43. Following the sale, the senior vice president now owns 270,134 shares of the company’s stock, valued at $6,675,011.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of TBPH. Norges Bank acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth about $22,422,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of Theravance Biopharma during the third quarter worth about $8,321,000. Vanguard Group Inc lifted its position in shares of Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after purchasing an additional 126,135 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after buying an additional 126,135 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $2,243,000. 84.42% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ TBPH opened at $22.95 on Tuesday. Theravance Biopharma has a 12 month low of $21.04 and a 12 month high of $35.48. The company has a debt-to-equity ratio of 6.52, a quick ratio of 5.41 and a current ratio of 5.41. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -5.75 and a beta of 1.69.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

Featured Story: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.